CoChat

ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer

Open access
Saad, Mohamed I, Alhayyani, Sultan, McLeod, Louise, Yu, Liang, Alanazi, Mohammad, Deswaerte, Virginie, Tang, Ke, Jarde, Thierry, Smith, Julian A, Prodanovic, Zdenka, Tate, Michelle D, Balic, Jesse J, Watkins, D Neil, Cain, Jason E, Bozinovski, Steven, Algar, Elizabeth, Kohmoto, Tomohiro, Ebi, Hiromichi, Ferlin, Walter, Garbers, Christoph, Ruwanpura, Saleela, Sagi, Irit, Rose‐John, Stefan, Jenkins, Brendan J · 2019 · EMBO Molecular Medicine
Cited by 136

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Oncogenic KRAS mutations are major drivers of lung adenocarcinoma (LAC), yet the direct therapeutic targeting of KRAS has been problematic. Here, we reveal an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. In genetically engineered and xenograft (human cell line and patient‐derived) KrasG12D‐driven LAC models, the specific blockade of ADAM17, including with a non‐toxic prodomain inhibitor, suppressed tumor burden by reducing cellular proliferation. The pro‐tumorigenic activity of ADAM17 was dependent upon its threonine phosphorylation by p38 MAPK, along with the preferential shedding of the ADAM17 substrate, IL‐6R, to release soluble IL‐6R that drives IL‐6 trans‐signaling via the ERK1/2 MAPK pathway. The requirement for ADAM17 in KrasG12D‐driven LAC was independent of bone marrow‐derived immune cells. Furthermore, in KRAS mutant human LAC, there was a significant positive correlation between augmented phospho‐ADAM17 levels, observed primarily in epithelial rather than immune cells, and activation of ERK and p38 MAPK pathways. Collectively, these findings identify ADAM17 as a druggable target for oncogenic KRAS‐driven LAC and provide the rationale to employ ADAM17‐based therapeutic strategies for targeting KRAS mutant cancers. Oncogenic KRAS mutations are associated with one‐third of lung adenocarcinoma (LAC) cases, yet the downstream molecular events that facilitate KRAS‐mediated tumorigenesis in the lung remain unresolved. This study reveals an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC. Oncogenic KRAS mutations are associated with one‐third of lung adenocarcinoma (LAC) cases, yet the downstream molecular events that facilitate KRAS‐mediated tumorigenesis in the lung remain unresolved. This study reveals an obligate requirement by oncogenic KRAS for the ADAM17 protease in LAC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201809976

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 136

Metadata

Authors
Saad, M. I., Alhayyani, S., McLeod, L., Yu, L., Alanazi, M., Deswaerte, V., Tang, K., Jarde, T., Smith, J. A., Prodanovic, Z., Tate, M. D., Balic, J. J., Watkins, D. N., Cain, J. E., Bozinovski, S., Algar, E., Kohmoto, T., Ebi, H., Ferlin, W., Garbers, C., Ruwanpura, S., Sagi, I., Rose‐John, S., & Jenkins, B. J.
Venue
EMBO Molecular Medicine
Published
2019-03-04
Volume
11
Issue
4
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2920126503
Cited by
136
References
17
FWCI
6.66
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer. https://app.cochat.ai/papers/10.15252/emmm.201809976
The paper
Saad, M. I., Alhayyani, S., McLeod, L., Yu, L., Alanazi, M., Deswaerte, V., Tang, K., Jarde, T., Smith, J. A., Prodanovic, Z., Tate, M. D., Balic, J. J., Watkins, D. N., Cain, J. E., Bozinovski, S., Algar, E., Kohmoto, T., Ebi, H., Ferlin, W., . . . Jenkins, B. J. (2019). ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201809976

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.